BioSpace News Archive

Lymphedema is a disease, characterized by an abnormal enlargement in the human body, owing to a damaged lymphatic system.

Biodesix, Inc. announced that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on August 8, 2022 in Vienna, Austria.

Siolta Therapeutics announced that the first newborn subject has been dosed in the adored study, a Phase 1b/2 trial of STMC-103H, a potential first-in-class microbiome-based therapeutic for the prevention of atopic diseases.

TELA Bio, Inc. today announced that it has been awarded a group purchasing agreement for Synthetic Bioabsorbable Mesh Products with Premier, Inc.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) of its Phase 1 clinical trial material that a now-resolved cyber-attack on the CMO’s computer systems as well as a planned annual maintenance shutdown will result in a delay in completing production of Skye’s Phase 1.

EmitBio, Inc., today announced the publication of a peer reviewed manuscript in the Journal of Medical Economics entitled “Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19.”

Bausch + Lomb Corporation announced Joseph C. Papa has stepped down as chair of the Board of Directors of the Company (the “Board”).

RIVANNA®, developers of world-first, imaging-based medical solutions, has appointed Jacob Katz as the senior director of sales and product management.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that Northside Hospital Cancer Institute has joined Caris’ Precision Oncology Alliance™.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that it has been selected to provide CDMO services to support the ongoing clinical development of a novel drug candidate in Europe.